| |
| |
 |
| |
|
|
| |
Partnerships |
|
| |
|
|
| |
To date, Plexxikon has signed major collaborations with Roche, Servier, Wyeth and Genentech,
and the company has received over $160 million in
non-dilutive funding from these partnerships.
Focus: Co-development and commercialization of PLX5568,
and other selective Raf inhibitors
Status: Phase 1
Total deal potential: Undisclosed
Includes $60 million upfront, over $275 million in
milestones for PKD, additional milestone sets for
multiple additional indications, plus royalties on sales
Co-promote option in U.S.
Focus: Co-development and commercialization of PLX4032, and other B-Rafv600E inhibitors
Status: Phase 1
Total deal potential: $706 million, plus royalties
Includes $46 million upfront and guaranteed funding
Co-promote option in U.S.
Focus: Discovery of non-peptidic renin inhibitors
Status: Preclinical development
Total deal potential: $100 million, plus royalties
Focus: Co-development of PPM-204 (PLX204), and other diabetes and obesity compounds
Status: Phase 2b
Total deal potential: $402 million, plus royalties
Includes $22 million upfront and guaranteed funding, and $50 million loan facility
Focus: Discovery of drug leads for single undisclosed kinase target
Status: Preclinical
Total deal potential: Includes upfront payment, multi-year research funding, milestones, plus royalties (terms undisclosed) |
|
| |
|
|
|
|
| |
| | | | | | |
| | | | | | | | |
| © 2007 Plexxikon Inc. | Site design by |
| |
|
|
